Immunotherapy Based on Immune Checkpoint Molecules and Immune Checkpoint Inhibitors in Gastric Cancer–Narrative ReviewReview Published on 2024-06-122024-09-05 Journal: International Journal of Molecular Sciences [Category] update2024, [키워드] CTLA-4 Gastric cancer Immune checkpoint inhibitors immune checkpoint molecules Immunotherapy PD-1 PD-L1 [DOI] 10.3390/ijms25126471 PMC 바로가기 [Article Type] Review
Deciphering the role of alternative splicing in neoplastic diseases for immune-oncological therapiesImmunology Review Published on 2024-04-262024-09-05 Journal: Frontiers in immunology [Category] update2024, [키워드] alternative splicing Antibody therapy CTLA-4 HLA-G Immune checkpoints PD-1 PD-L1 [DOI] 10.3389/fimmu.2024.1386993 PMC 바로가기 [Article Type] Immunology Review
Classical monocytes-low expressing HLA-DR is associated with higher mortality rate in SARS-CoV-2+ young patients with severe pneumoniaResearch Article Published on 2024-01-092024-09-05 Journal: Heliyon [Category] update2024, [키워드] COVID-19 HLA-DR Monocytes PD-L1 Pneumonia SARS-CoV-2 young adults [DOI] 10.1016/j.heliyon.2024.e24099 PMC 바로가기 [Article Type] Research Article
Anti-PD-L1 therapy altered inflammation but not survival in a lethal murine hepatitis virus-1 pneumonia modelImmunology Original Research Published on 2024-01-082024-09-05 Journal: Frontiers in immunology [Category] update2024, [키워드] ACE ACE2 CD66a COVID-19 Immunotherapy MHV-1 PD-L1 Pneumonia [DOI] 10.3389/fimmu.2023.1308358 PMC 바로가기 [Article Type] Immunology Original Research
In silico evolution of autoinhibitory domains for a PD-L1 antagonist using deep learning modelsarticle Published on 2023-11-302024-09-05 Journal: Proceedings of the National Academy of Sciences of [Category] update2024, [키워드] computational protein design de novo protein design deep learning PD-L1 protein–protein interactions [DOI] 10.1073/pnas.2307371120 PMC 바로가기 [Article Type] article
A Phase 1 Trial of Durvalumab in Combination with Bacillus Calmette-Guerin or External Beam Radiation Therapy in Patients with Bacillus Calmette-Guerin–unresponsive Non–muscle-Invasive Bladder Cancer: The Hoosier Cancer Research Network GU16–243 ADAPT-BLADDER StudyArticle Published on 2023-03-122024-09-05 Journal: European urology [Category] update2024, [키워드] Bacillus Calmette-Guérin Bacillus Calmette-Guerin unresponsive Bladder cancer clinical trial durvalumab Non–muscle invasive PD-L1 Radiation urothelial carcinoma [DOI] 10.1016/j.eururo.2023.01.017 PMC 바로가기 [Article Type] Article
CD8 + T cell-intrinsic IL-6 signaling promotes resistance to anti-PD-L1 immunotherapyarticle Published on 2023-01-032024-09-05 Journal: Cell Reports Medicine [Category] update2024, [키워드] atezolizumab Cancer CD8 T cell checkpoint blockade immunotherapy clinical trial IL-6 interleukin 6 PD-L1 [DOI] 10.1016/j.xcrm.2022.100878 PMC 바로가기 [Article Type] article
Atezolizumab for the treatment of advanced recurrent basal cell carcinoma and urothelial carcinoma of bladder: a case reportArticle Published on 2022-10-312022-11-15 Journal: Journal of Medical Case Reports [Category] 진단, [키워드] Administered Advanced basal cell carcinoma atezolizumab bladder Bladder cancer Cancer cancers carried Case report Cell Checkpoint inhibitor chemotherapeutic agent clinician Comorbidity Complete Compliance complication of COVID-19 cumulative Definitive disease dose female histology hospital increasingly indicated Infection inhibitor knowledge lymph nodes Metastasis metastatic Metastatic muscle-invasive bladder cancer Patient PD-L1 PD-L1 inhibitor. positive progressed Radiotherapy reached receiving Side effects smoking synchronous the patient therapy transurethral resection treated Treatment tumors [DOI] 10.1186/s13256-022-03634-x PMC 바로가기
Booster dose of mRNA vaccine augments waning T cell and antibody responses against SARS-CoV-2Article Published on 2022-10-122022-11-16 Journal: Frontiers in Immunology [Category] COVID19(2023년), SARS, 변종, [키워드] activated T cell antibodies antibody Antibody Response booster booster dose booster vaccination CD137 CD69 CD8 T cell Cellular immune response ChAdOx1-S conducted decrease dose expressing expression Frequency humoral IFN-γ immune response immunosuppressive increase in indicated Infection Injections lack longitudinal analysis memory monocyte mRNA mRNA vaccine myeloid cell omicron participant PD-L1 peptides phenotype producing protective immunity reactive reduced SARS-CoV-2 SARS-CoV-2-specific T cell T cell T cell response T cells the spike protein TNF-α upregulation vaccination Vaccinations Vaccine variant vector vaccine virus-specific T cell [DOI] 10.3389/fimmu.2022.1012526 PMC 바로가기
A newly discovered PD-L1 B-cell epitope peptide vaccine (PDL1-Vaxx) exhibits potent immune responses and effective anti-tumor immunity in multiple syngeneic mice models and (synergizes) in combination with a dual HER-2 B-cell vaccine (B-Vaxx)새로 발견된 PD-L1 B세포 에피토프 펩타이드 백신(PDL1-Vaxx)은 여러 동종 유전자 마우스 모델에서 강력한 면역 반응과 효과적인 항종양 면역을 나타내며, 이중 HER-2 B세포 백신(B-Vaxx)과 병용 시 시너지 효과를 발휘합니다.Article Published on 2022-10-052024-08-19 Journal: Oncoimmunology [Category] 파상풍, [키워드] B-cell epitope CT26 D2F2/E2 Immunotherapy PD-L1 Peptide-vaccine